Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination von Townsley, Carol A, Pond, Gregory R, Oza, Amit M, Hirte, Hal W, Winquist, Eric, Goss, Glenwood, Degendorfer, Pamela, Moore, Malcolm J, Siu, Lillian L

Volltext

A priority educational program at Princess Margaret Cancer Centre von Grant, Jasmine, Sellmann, Susanna, Gundry, Julie, Degendorfer, Pamela

Volltext

Optimizing clinical research procedures in public health emergencies von Madariaga, Ainhoa, Kasherman, Lawrence, Karakasis, Katherine, Degendorfer, Pamela, Heesters, Ann M., Xu, Wei, Husain, Shahid, Oza, Amit M.

Volltext

Quality assurance metrics in clinical trial conduct von Li, Jennifer, Sellmann, Susanna, Philip, Lindsay, Guglielmi, Cristina, Degendorfer, Pamela, Oza, Amit M.

Volltext

Equity of access: Consent interpretation program at Princess Margaret Cancer Centre (PM) in Canada von Grant, Jasmine, Philip, Lindsay, Eagan, Grace, Abraham, Elizabeth, Degendorfer, Pamela, Oza, Amit M.

Volltext

Equity of access: Consent interpretation program at Princess Margaret Cancer Centre (PM) in Canada von Grant, Jasmine, Philip, Lindsay, Eagan, Grace, Abraham, Elizabeth, Degendorfer, Pamela, Oza, Amit M.

Volltext

Mobile solution for clinical research documentation von Philip, Lindsay, Grant, Jasmine, Eggert, Calven, Di Nardo, Aaron, Sellmann, Susanna, Cole, Heather, Flynn-Post, Marcia, Williams-Brennan, Leslie, Degendorfer, Pamela

Volltext

Mobile solution for clinical research documentation von Philip, Lindsay, Grant, Jasmine, Eggert, Calven, Di Nardo, Aaron, Sellmann, Susanna, Cole, Heather, Flynn-Post, Marcia, Williams-Brennan, Leslie, Degendorfer, Pamela

Volltext

A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor von Hao, Desiree, Chu, Quincy, Welch, Stephen, Yau, Cindy Y. F., Spratlin, Jennifer L., Tang, Patricia, MacKenzie, Mary J., Townsley, Carol A., Arndt, Diane, Johnson, Laureen, Trapsa, Daniela, Degendorfer, Pamela, Kulkarni, Sujay, Jawlekar, Gajendra, Dhobe, Poornima, Oza, Amit M.

Volltext

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia von Gomez-Abuin, Gonzalo, Winquist, Eric, Stadler, Walter M, Pond, Greg, Degendorfer, Pamela, Wright, John, Moore, Malcolm J

Volltext

Maternal and fetal outcome after breast cancer in pregnancy von Zemlickis, Donna, Lishner, Michael, Degendorfer, Pamela, Panzarella, Tony, Burke, Bonnie, Sutcliffe, Simon B., Koren, Gideon

Volltext

Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Commentary von TOWNSLEY, Carol A, POND, Gregory R, CHRISTIAN, Michaele C, OZA, Amit M, HIRTE, Hal W, WINQUIST, Eric, GOSS, Glenwood, DEGENDORFER, Pamela, MOORE, Malcolm J, SIU, Lillian L, TRIMBLE, Edward L

Volltext

Maternal and fetal outcome after invasive cervical cancer in pregnancy von ZEMLICKIS, D, LISHNER, M, DEGENDORFER, P, PANZARELLA, T, SUTCLIFFE, S. B, KOREN, G

Volltext